- Home
- MESO vs PDM Comparison
MESO vs PDM Comparison
Compare MESO & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- PDM
- Stock Information
- Founded
- MESO 2004
- PDM 1997
- Country
- MESO Australia
- PDM United States
- Employees
- MESO N/A
- PDM N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- PDM Building operators
- Sector
- MESO Health Care
- PDM Real Estate
- Exchange
- MESO Nasdaq
- PDM Nasdaq
- Market Cap
- MESO 1.3B
- PDM 921.9M
- IPO Year
- MESO N/A
- PDM N/A
- Fundamental
- Price
- MESO $11.06
- PDM $7.55
- Analyst Decision
- MESO Buy
- PDM Buy
- Analyst Count
- MESO 4
- PDM 5
- Target Price
- MESO $18.00
- PDM $9.40
- AVG Volume (30 Days)
- MESO 207.3K
- PDM 900.6K
- Earning Date
- MESO 08-28-2025
- PDM 07-28-2025
- Dividend Yield
- MESO N/A
- PDM 6.63%
- EPS Growth
- MESO N/A
- PDM N/A
- EPS
- MESO N/A
- PDM N/A
- Revenue
- MESO $5,670,000.00
- PDM $568,472,000.00
- Revenue This Year
- MESO $178.09
- PDM $0.50
- Revenue Next Year
- MESO $305.06
- PDM N/A
- P/E Ratio
- MESO N/A
- PDM N/A
- Revenue Growth
- MESO N/A
- PDM N/A
- 52 Week Low
- MESO $5.78
- PDM $5.46
- 52 Week High
- MESO $22.00
- PDM $11.12
- Technical
- Relative Strength Index (RSI)
- MESO 50.57
- PDM 59.71
- Support Level
- MESO $10.32
- PDM $7.33
- Resistance Level
- MESO $11.32
- PDM $7.72
- Average True Range (ATR)
- MESO 0.34
- PDM 0.19
- MACD
- MESO 0.04
- PDM 0.01
- Stochastic Oscillator
- MESO 36.70
- PDM 86.15
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.